Vaxcyte launches proposed $500M public offering of stock, warrants
Source: SeekingAlpha
2026-01-29 16:20:24 ET
More on Vaxcyte
- Vaxcyte: Financial Durability And The Case For Disruption
- Vaxcyte, Inc. (PCVX) Presents at Jefferies London Healthcare Conference 2025 - Slideshow
- Vaxcyte, Inc. (PCVX) Presents at Jefferies London Healthcare Conference 2025 Transcript
- Moderna, vaccine makers decline following FDA official comments on future approvals
- Seeking Alpha’s Quant Rating on Vaxcyte
Read the full article on Seeking Alpha
For further details see:
Vaxcyte launches proposed $500M public offering of stock, warrants
Vaxcyte Inc.
NASDAQ: PCVX
PCVX Trading
1.88% G/L:
$59.48 Last:
305,219 Volume:
$58.47 Open:
PCVX Latest News
February 24, 2026 04:05:00 pm
Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
February 11, 2026 04:05:00 pm
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines
February 10, 2026 04:05:00 pm
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026
PCVX Stock Data
$7,801,730,421
136,657,209
0.01%
97
N/A
Biotechnology & Life Sciences
Healthcare
US
San Carlos
